CN106555004B - The lncRNA markers of cerebral arterial thrombosis - Google Patents

Abstract

The invention discloses the lncRNA markers of cerebral arterial thrombosis, the lncRNA markers are LINC00189 and LOC105376014, wherein LINC00189 up-regulated expressions in ischemic cerebral stroke patients, LOC105376014 express downward in ischemic cerebral stroke patients.LncRNA markers provided by the present invention, can be used for the early diagnosis of cerebral arterial thrombosis, have higher sensitivity and specificity.

Description

The lncRNA markers of cerebral arterial thrombosis

Technical field

The invention belongs to biomedicine fields, are related to the lncRNA markers of cerebral arterial thrombosis.

Background technology

Great public health problem of the cerebral apoplexy as the whole world, is a kind of brain blood circulation disorder disease of unexpected onset Disease, and one of the principal disease that endangers human health.Cerebral apoplexy has become the worldwide second largest cause of death and cause Residual first cause.In dead crowd caused by palsy, developing country is concentrated on more than 2/3rds.There is data to show, About 2.3 hundred million people of China suffers from cardiovascular disease, and patients with cerebral apoplexy is more than 7,000,000.One includes 169,871 40 years old or more adults The perspective queue of people, which is ground, to make internal disorder or usurp the results show that cerebral apoplexy occupies the 3rd cause of the death of male and the 2nd cause of the death of women, male's brain The palsy death rate is 310.5/100,000 man-year, accounts for the 21.6% of total death, and the women palsy death rate is 242.3/100,000 Man-year accounts for the 20.8% of total death.High incidence, high relapse rate, high disability rate and the high lethality of cerebral apoplexy give patient home White elephant is caused with society.There is data to show, the expense that China is used to treat cerebral apoplexy every year is up to tens billion of first people People's coin, cerebral apoplexy have become the important Disease Spectrum in China and great public health problem.Cerebral arterial thrombosis is also known as Cerebral infarction, it is the local brain tissue area blood supply obstacle caused by a variety of causes, leads to brain tissue ischemia anoxic venereal disease Become necrosis, and then generates clinically corresponding neurological deficit performance.Ischemic Stroke is the main Types of palsy, accounts for about soldier In always fall ill 60%~80%.At present it has been recognized that cerebral apoplexy is a kind of coefficient by environmental factor, inherent cause etc. The relationship of complex disease, the pathogenesis and inherent cause that understand cerebral apoplexy to the early diagnosis of cerebral apoplexy and prevents to have important Meaning.

With the rapid development of microarray technology and Nucleic acid sequencing techniques, scientist has found only 2% in human genome Sequential coding generate protein, protein coding gene number deficiency 30,000, and remaining nearly 98% genome sequence turns Record produces a large amount of and miscellaneous non-coding RNA, these ncRNA are the important sets of complicated regulated and control network in body At part.

Long-chain non-coding RNA (long noncoding RNA, lncRNA), which is one kind, to be sent out during various biological Wave the macromolecular ncRNA of regulating and controlling effect.Its is widely distributed, and length is typically greater than 200 bases, due to lacking effective open reading The ability of frame (ORF) and nothing or few coding albumen.As a uncharted field in molecular biology, lncRNA be with The form of RNA played on many levels controlling gene expression effect, mainly epigenetic regulation, transcriptional control and Three levels of post-transcriptional control are regulated and controled.As the important component of mammalian transcription group, the function of lncRNA is current It need to be furtherd investigate.Initial lncRNA is considered as the by-product of rna plymerase ii transcription, is that subgenomic transcription " is made an uproar Sound ", " dark matter " do not have biological function.But result of study in recent years is shown, lncRNA is in cell normal physiological activity Important function and participate in the occurrence and development of kinds of tumors and other diseases.LncRNA not only participates in transport in core, turns Record in the cellular physiological events such as regulation and control, protein degradation, genomic imprinting and X chromosome silence, also with breast cancer, prostate cancer, The pathogenesis of the diseases such as non-small cell lung cancer, lymphatic leukemia is related.LncRNA can pass through Genomic Imprinting, chromatin weight Structure shears the mechanism such as regulation and control, mRNA degradations and translational control to implement its function.Although lncRNA correlative studys obtain in recent years Progress, but its function and mechanism of action still need further to be explored.Research lncRNA main methods and tool include chip, RNA sequencings, real-time quantitative PCR, Northern blotting, in situ hybridization, RNAi, RIP and Bioinformatics Prediction etc..It grinds The development and utilization for studying carefully technology is very crucial for the research of biological mechanism.

LncRNA is widely present in Various Tissues, and expression has tissue specificity and Space-time speciality.Meanwhile LncRNA also has the expression pattern of specificity in tumour and other diseases.At present for lncRNA in cerebral disease field Research is still in the starting stage, seeks effects of the lncRNA in cerebral arterial thrombosis and is of great significance.

Invention content

In order to make up for the deficiencies of the prior art, an object of the present invention provides a kind of examining for early stage cerebral arterial thrombosis Stopping pregnancy product make patient just be prevented in early days, and then improve survival rate and quality of life.

The second object of the present invention provides a kind of diagnostic method of cerebral arterial thrombosis, by the expression for detecting lncRNA Level come diagnose patient whether suffer from cerebral arterial thrombosis.

The third object of the present invention provides a kind of molecular marker, the Testing index as clinical application.

To achieve the goals above, the present invention adopts the following technical scheme that：

The present invention provides a kind of cerebral arterial thrombosis diagnosis lncRNA markers, the lncRNA includes LINC00189。

In the present invention, LINC00189 refers to gene or the mRNA from the genetic transcription, in the mankind, is located at No. 21 chromosomes Long-armed 2nd area, 1 band, 3 subzone.There are three annotation transcripts (or splice variant) for gene tool：The LINC00189-001 of long 989bp The LINC00189-003 of (the transcript ID in Ensembl is ENST00000420364.1), long 783bp (turn in Ensembl It is ENST00000447125.5 to record this ID) and the LINC00189-002 of long 308bp (the transcript ID in Ensembl is ENST00000431661.1).In specific embodiments, LINC00189 gene outcomes refer to long transcript.

Further, the sequence of the LINC00189 is as shown in SEQ ID NO.1.

Further, the lncRNA markers further include LOC105376014, which is located at No. 9 the short arm of a chromosome 2 Area 1 takes, including two transcripts, the XR_ that the XR_929550.2.1 and length that length is 1335bp are 938bp 001746646.1.1.In the specific implementation mode of the present invention, LOC105376014 refers to long transcript, sequence such as SEQ ID Shown in NO.2.

The present invention provides above-mentioned lncRNA biomarkers in preparing or screening cerebral arterial thrombosis diagnostic products Application.

Further, the product includes：Pass through sequencing technologies, nucleic acid hybridization technique, nucleic acid amplification technologies or immunoassays Method detect the expression of lncRNA recited above.In the present invention, LINC00189 is in ischemic cerebral stroke patients Up-regulated expression, LOC105376014 express downward in ischemic cerebral stroke patients.

Further, the nucleic acid amplification technologies are selected from PCR, reverse transcriptase polymerase chain reaction, transcription Jie Amplification, ligase chain reaction, strand displacement amplification and the amplification based on nucleic acid sequence led.

The present invention provides a kind of product, the product includes chip, preparation or kit, can be measured in sample such as The expression of the upper lncRNA.

Further, the chip includes：Solid phase carrier；And the oligonucleotides being orderly fixed on the solid phase carrier is visited Needle, the oligonucleotide probe specifically correspond to some or all of lncRNA recited above sequences.Wherein, solid phase carries Body includes but is not limited to sheet glass, silicon chip, polypropylene screen, nitrocellulose filter, nylon membrane or polystyrene film.

Further, the kit includes that probe, genetic chip or the PCR of the specificity for detecting above-mentioned lncRNA draw Object.

Further, the PCR primer sequence such as SEQ ID NO.3 and SEQ ID NO.4 institutes of LINC00189 specificity are detected Show；The PCR primer sequence of LOC105376014 specificity is detected as shown in SEQ ID NO.5 and SEQ ID NO.6.

Further, it is described state kit may also include dNTP, random primer, reducing agent, RNase inhibitor, reverse transcriptase, MgCl₂With one or more combinations in PCR buffer solutions etc., in addition, the kit can also contain standard items and/or right According to product；In the preference of the present invention, select GAPDH as internal reference.

Further, mentioned reagent box includes also preferably some other auxiliary reagent, and the auxiliary reagent is quantitative PCR Some conventional use of reagents in amplification kit, the characteristic of these reagents and their preparation method are art technologies Known to personnel；The reagent such as (but not limited to)：Negative controls, positive reference substance；It can also be fixed including fluorescence Measure PCR reaction plates, PCR reaction plate sealed membranes etc..

The present invention provides application of the said goods in the tool for preparing diagnosing ischemia cerebral apoplexy.

The present invention provides a kind of product of diagnosing ischemia cerebral apoplexy, the product can be by detecting in sample The expression of LINC00189 carrys out diagnosing ischemia cerebral apoplexy." sample " include cell, tissue, internal organs, cerebrospinal fluid, body Liquid (blood, lymph etc.), digestive juice, expectoration, alveole bronchus cleaning solution, urine, excrement etc..Preferably, the sample is group It knits, blood.In the specific implementation mode of the present invention, sample is blood.

" probe " refers to the molecule that can be combined with the particular sequence of another molecule or subsequence or other parts.Unless otherwise finger Go out, term " probe " is often referred to match by complementary base and (often referred to as " target polynucleotide ") be combined with another polynucleotides Polynucleotide probes.According to the preciseness of hybridization conditions, probe energy and the target for lacking sufficient sequence complementarity with the probe are more Nucleotide combines.Probe can make direct or indirect label, and range includes primer.Crossing system includes, but are not limited to：It is molten Liquid phase, solid phase, mixed phase or in situ hybridization measuring method.

The probe has the base sequence with the specific base sequence complementary of target gene.Here, so-called " complementation ", As long as hybridization, can not be complete complementary.These polynucleotides have usually relative to the specific base sequence 80% or more, preferably 90% or more, more preferable 95% or more, particularly preferred 100% homology.These probes can be DNA, Can also be RNA, furthermore it is possible to pass through PNA (Polyamide nucleic in part of it or whole nucleotides Acid, peptide nucleic acid), LNA (registered trademark, locked nucleic acid, Bridged Nucleic Acid, Cross-linked core Acid), ENA (registered trademark, 2 '-O, 4 '-C-Ethylene-bridged nucleic acids), GNA (Glycerol Nucleic acid, glycerine nucleic acid), the artificial replacement nucleic acid such as TNA (Threose nucleic acid, threose nucleic acid) obtains Polynucleotides.

It includes LINC00189 and LOC105376014 that gene detecting kit or genetic chip, which can be used for detecting, in the present invention The expression of multiple genes (for example, with the relevant multiple genes of cerebral arterial thrombosis) including gene, by ischemic cerebral apoplexy In multiple markers be carried out at the same time detection, be greatly improved cerebral arterial thrombosis diagnosis accuracy rate.

It would be recognized by those skilled in the art that the practicability of the present invention is not limited to the marker gene of the present invention The gene expression of any specific variants is quantified.As unrestricted example, marker gene can have SEQ ID NO.1 And/or the cDNA sequence that SEQ ID NO.2 are specified.In some embodiments, have and listed sequence at least 85% phase With or similar cDNA sequence, such as above-mentioned listed sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% same or analogous cDNA sequence.

In the present invention, term " homology " " refers to complementary degree.There may be Homoeology or complete homologys (that is, homogeneity).The sequence of partial complementarity is to inhibit the nucleic acid molecules and " substantially homologous " of complete complementary at least partly The nucleic acid molecules of target nucleus acid hybridization.Fully-complementary sequence can be by making with the inhibition of target sequence hybridized under the conditions of low strict It is checked with hybridization assays (Southern or Northern traces, solution hybridization etc.).Substantially homologous sequence or probe It will compete and inhibit complete homologous nucleic acid molecules under the conditions of low strict and the combination of target (that is, hybridization).This is not It says, low strict condition is to allow the condition of non-specific binding；Low strict condition requires between two sequences The interaction for being combined into specificity (that is, selectivity).Being not present for non-specific binding can be by using substantially non-mutual The second target for mending (for example, being below about 30% homogeneity) is tested；There is no non-specific binding, probe Will not with the second incomplementarity target hybridization.

In the present invention, term " stringency ", which is used to refer to, carries out the residing condition of nucleic acid hybridization：Temperature, ionic strength and its The presence of his compound (such as organic solvent).Under " low stringency condition ", nucleic acid sequence of interest will be with its exact complementarity Sequence, the sequence with single base mispairing, closely related sequence (for example, sequence with 90% or more high homology) with And the sequence (for example, sequence with 50-90% homologys) of only Homoeology hybridizes.At " medium stringent conditions " Under, nucleic acid sequence of interest by only with its exact complementary sequence, the sequence with single base mispairing and closely related sequence Arrange (for example, 90% or more high homology) hybridization.Under " high stringency condition ", nucleic acid sequence of interest will be only accurate with it Complementary series and the sequence of (condition for depending on such as temperature) with single base mispairing hybridize.In other words, in high stringency Property under the conditions of, temperature can be increased to exclude to hybridize with the sequence of single base mispairing.

The LINC00189 gene product expressions up-regulation referred in the present invention, refers to the higher level than normal presence.It is logical Often, this can be by estimating with comparing.According to specific embodiment, the increased levels of lncRNA are higher than compareing 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 100%, 150%, 200% or very To higher level.According to another specific embodiment, it is intended that LINC00189 gene product expressions or presence, and its (or in control) lacks under normal circumstances.In other words, in these embodiments, LINC00189 gene outcomes are measured to increase The expression added is equivalent to the presence of detection LINC00189 gene outcomes.In general, this is in this case, will include compareing to ensure Detection reaction is correct to be carried out.

The LOC105376014 expression referred in the present invention is lowered, and refers to the lower level than normal presence, this can pass through Estimate with comparing, suitable control includes but not limited to similar sample, control from the subject for not having cerebral apoplexy LOC105376014 gene outcome average levels faces in the average level of group (or control cell) or one group of related sampling tissue Bed data.

The advantages of the present invention：

Present invention firstly discovers that with cerebral arterial thrombosis occurrence and development relevant lncRNA, by detecting the lncRNA's Expression can be detected early stage cerebral arterial thrombosis, to be treated to early stage ischemic cerebral stroke patients, carry The life quality of high patient.

Biomarker provided by the invention carries out Combining diagnosis, can be stronger with sensitivity higher, specificity.

Description of the drawings

Fig. 1 shows the difference expression gene using cDNA microarray ischemic cerebral stroke patients；

Fig. 2 shows the expression in ischemic cerebral stroke patients using QPCR detections lncRNA.

Specific embodiment

The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip Part, such as Sambrook et al., molecular cloning：Laboratory manual (New York:Cold Spring HarborLaboratory Press, 1989) condition described in, or according to the normal condition proposed by manufacturer.

Embodiment 1 is screened and the relevant gene marker of cerebral arterial thrombosis

1, sample collection

Each blood for collecting 10 normal human bloods and ischemic cerebral stroke patients, the equal informed consent of patient are above-mentioned all Agreement of the acquirement of sample by the committee of organizational ethics.

2, the preparation of RNA sample

1) 12000rpm high speed centrifugation 10min after clinical serum sample collection, are repeated 2 times, -80 DEG C of guarantors of gained serum sample It deposits；

2) 4 DEG C of defrostings of serum sample are frozen；

3) serum sample for drawing 250 μ 1 is managed to 1.5m1EP, adds 750 μ 1Trizol LS Reagent, blows and beats mixing, quiet Set 5min；

4) chlorination imitates (CHCl₃：trizol250μ1:750 μ 1), mixing is overturned, 15min is stood；

5) 4 DEG C, 12000rpm, 15min is centrifuged；

6) supernatant liquid is carefully drawn to a new EP pipes；

7) add appropriate isopropanol (isopropanol：trizo1500μ1：750 μ 1), mixing is overturned, 10min is stood；

8) 4 DEG C, 12000rpm centrifuges 10min；

9) upper layer centrifugate is abandoned, 75% ethyl alcohol (RNA enzyme inactivation) is added；

10) 4 DEG C, 8000rpm centrifuges 5min；

11) retain precipitation, abandon upper layer centrifugate, be stored at room temperature 5-10min；

12) appropriate DEPC water dissolutions precipitation takes appropriate RNA solution to survey concentration and observation RNA extracting situations；

13) title, concentration and mouth phase, -80 DEG C of preservations are marked.

3, reverse transcription and label

With Low RNA Input Linear Amplification Kit by mRNA reverse transcriptions at cDNA, while using Cy3 Labelling experiment group and control group respectively.

4, hybridize

Genetic chip uses Kang Cheng biology-Human lncRNAArray, is carried out by the step of chip operation instructions miscellaneous It hands over.

5, data processing

Chip Agilent scanner scannings after hybridization, resolution ratio are 5 μm, and scanner is automatically with 100% and 10%PMT Each scanning 1 time, 2 times result Agilent softwares merge automatically.Scan image data is using at Feature Extraction Reason analysis, obtained initial data application Bioconductor program bags carry out follow-up data processing.Last Ratio values are experiment Group and control group.Differential gene screening criteria：Ratio >=4 are up-regulation gene, and ratio≤0.25 is down-regulated gene.

6, result

The results are shown in Figure 1, compared with healthy human blood, expression water of the LINC00189 in ischemic cerebral stroke patients The flat expression for being significantly higher than Healthy People；Expressions of the LOC105376014 in ischemic cerebral stroke patients is substantially less than The expression of Healthy People.

The differential expression of 2 QPCR sequence verification LINC00189 genes of embodiment

1, large sample QPCR verifications are carried out to the lncRNA of gene differential expression.According to the sample collection side in embodiment 1 Formula selects each 100 of the blood sample sample of normal person and ischemic cerebral stroke patients.

2, RNA extraction steps are the same as embodiment 1.

3, reverse transcription：

(1) reverse transcription reaction：

Using 25 μ l reaction systems, each sample takes 1 μ g total serum IgEs as template ribonucleic acid, is separately added into PCR pipe following Component：DEPC water, 5 × RT Buffer, 10mM dNTP, 0.1mM DTT, 30 μM of OligodT, 200U/ μ l M-MLV, mould Plate RNA.42 DEG C are incubated 1h, 72 DEG C of 10min, of short duration centrifugation.(2) design of primers：

The primer sequence of LINC00189 genes is：

Forward primer：5’-TCTTTGATTGACTGATTCTTT-3’(SEQ ID NO.3)

Reverse primer：5’-TTGAGGAACACATCTGAA-3’(SEQ ID NO.4)

The primer sequence of LOC105376014 genes is：

Forward primer：5’-TTGTTCTTGTGTCTGTTCT-3’(SEQ ID NO.5)

Reverse primer：5’-CTGCTACTGTGCTTCTAC-3’(SEQ ID NO.6)

The primer sequence of house-keeping gene GAPDH is：

Forward primer：5’-CCGGGAAACTGTGGCGTGATGG-3’(SEQ ID NO.7)

Reverse primer：5’-AGGTGGAGGAGTGGGTGTCGCTGTT-3’(SEQ ID NO.8)

(3) QPCR amplifications are examined：

Using 25 μ l reaction systems, 3 parallel pipes are arranged in each sample, and all amplified reactions are repeated three times above to protect Demonstrate,prove the reliability of result.

Prepare following reaction system：12.5 μ l of SYBR Green PCRs system, forward and reverse primer (5 μM) Each 1 μ l, template cDNA 2.0 μ l, 8.5 μ l of no enzyme water.Operations are carried out on ice.

Amplification program is：95 DEG C of 60s, (95 DEG C of 15s, 60 DEG C of 15s, 72 DEG C of 45s) × 35 cycles.

Using SYBRGreen as fluorescent marker, it is anti-that PCR is carried out on Light Cycler fluorescence real-time quantitative PCR instrument It answers, determines that purpose band, Δ Δ CT methods carry out relative quantification by melt curve analysis analysis and electrophoresis.

3, statistical method

Experiment is all completed according to being repeated 3 times, and result data is indicated in a manner of mean+SD, Using SPSS18.0 statistical softwares come for statistical analysis, difference between the two is examined using t, it is believed that works as P<Have when 0.05 It is statistically significant.

4, result

The results are shown in Figure 2, compared with Healthy People, LINC00189 genes up-regulated expression in ischemic cerebral stroke patients, Expression of the LOC105376014 in ischemic cerebral stroke patients is lowered, and difference has statistical significance (P<0.05), same to chip Testing result is consistent.

The explanation of above-described embodiment is only intended to understand the method and its core concept of the present invention.It should be pointed out that for this For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention And modification, these improvement and modification will also be fallen into the protection domain of the claims in the present invention.

SEQUENCE LISTING

<110>The First Hospital of Medical College of Shantou University

<120>The lncRNA markers of cerebral arterial thrombosis

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 989

<212> DNA

<213>People source

<400> 1

ttacaagtga actttctttc ctgttttaaa gccttttaaa taaacttcca ctcctgtgct 60

gaaacttgcc ttagtctttt tttctgcttt atgcccctca gtcgaattct ttcatctgag 120

gaggcaagaa ttgaagttgc tgcagacgcc tgtggattca ccacaagtac attggagtaa 180

ccactgggaa caacaggttg ccttagaagc tttgcaggtt gttttgtttt tttgtttgtt 240

tgtttttttg agacggggtc tcactttgtc gcccaggttt gttgcccagg ctggagtgca 300

gtggcgcaat ctcggctctc cgcaacctct gcctcccggg ctcaagtgat cctcccacct 360

cggcttcccg agtacctggg actacaggca tgcaccacca cacccggcta attttaattt 420

ttattttgta tttttagtag agttggggtt tcaccatgtt cccagctggt cttgaactct 480

tgaggtgaag caatccgccc acctcagcct cccaaagtgc tgagattaca gacgtgagcc 540

atcgcgccta gccttgcaag ttgttttttg ttgaacagaa gaagctattc aaaaatgtcc 600

aggactctgt tatttattca gcaagcttac aaagccatct ttgattgact gattctttga 660

caatgactat ctggatgaca caggaaggat gcaattctgg ccttggagag aaaacttgca 720

aggaaaggaa catgtttgaa tttcagatgt gttcctcaat gaatcacgat cttcagggaa 780

tgtttcaggt ggaggaaggg gctcttggtc aatgagcctg aagactgcat ggcaaccttt 840

gccagctttt ggcctgaaaa ctcaacttct tcatttgaga taattcctgt tttatatact 900

ttcatttgag atattcctgg tgtatcaact gaaacaaaat ctatgaaata tcagattcac 960

aaaaatacat tttgaatatt gaacgtgga 989

<210> 2

<211> 1335

<212> DNA

<213>People source

<400> 2

ttatttgaat ttcaaacaac agaccaacca tagctcaatg tttctcaaga gtatcctgtg 60

gagcacagtg cgtgaacgcc cagaagaaag cagtctgtgg tcaggtgggt ttctgtgcca 120

tttgctgcca ccttccctgc aaacagtgat ttacagcaca cattgttctt gtgtctgttc 180

tgcagtgata aaacccattt aactcagtgg ttcccaaatg tactgaccgt ggaactgttt 240

tactcagggg acactgttaa catcctgtag aagcacagta gcaggtatcc agcctgcata 300

cgataagaca accagaacca aatttggcag gtacatgtct ggaactctgt ttcattatgc 360

cgtaaaataa aactacgaat ttcattcaac aaatctgtac tgaataagta ggcttcactc 420

ttgggatgtc aacttttaaa acttacttaa tatcagctat cgttatataa tctttgttca 480

taatgacgct gtctggttga acacaaactg gctgggtgtt aaattccact tgtgtttatg 540

atatttaata atgtcctaag aaggcagcca gtagaacctt ggctactgtt tttcaaaagt 600

ggctctgcat tgctcctaca taaccccgta cattactcca cagtcctgtt agagccctga 660

aagggaaact gctaaaaata aggttcttca tttaggtgac taggaactcc caatattttt 720

gccctaggga atactgggag acaaatctct acgatcacaa attactaatg gtttccccag 780

aactgctggt ggccatatcc cctggcatgt ggaagggccc agaagaggcc actctactgc 840

agaggccaac agaagagtgt tgcccaggct ggtctcaaac ttctgggctc aagcaaccct 900

ccagcctcgg cctcccaaag tgttgggatc ataggcatga gacaccgtgc ctggcgaaga 960

tatttttacc gaaaaggaca gagggtgtac ttggaggcac ataccaaaga aatgccatgt 1020

gagaacaagc aagaaggtgg ccatctgtaa accaggaaga gtgtcctcac cagaaaatga 1080

agtggcttca actttgatct cagaattcca gcctccataa ctgtgagaaa atacatttct 1140

gttctttcag ccagtctatg gcattacatt atagcaaccc aagcaaacta aggcatgccc 1200

agaaatgact acaggggtaa aaatgagcag ataattggtt tttagtgtcc tgaagtttat 1260

ctgcttttcc ttatgtactt atatcgttgc cactgccacc aggctactct tccttcttgt 1320

ctgctcccaa acagg 1335

<210> 3

<211> 21

<212> DNA

<213>Artificial sequence

<400> 3

tctttgattg actgattctt t 21

<210> 4

<211> 18

<212> DNA

<213>Artificial sequence

<400> 4

ttgaggaaca catctgaa 18

<210> 5

<211> 19

<212> DNA

<213>Artificial sequence

<400> 5

ttgttcttgt gtctgttct 19

<210> 6

<211> 18

<212> DNA

<213>Artificial sequence

<400> 6

ctgctactgt gcttctac 18

<210> 7

<211> 22

<212> DNA

<213>Artificial sequence

<400> 7

ccgggaaact gtggcgtgat gg 22

<210> 8

<211> 25

<212> DNA

<213>Artificial sequence

<400> 8

aggtggagga gtgggtgtcg ctgtt 25

Claims (8)

1. Application of the 1.lncRNA biomarkers in preparing or screening cerebral arterial thrombosis diagnostic products, which is characterized in that institute It includes LINC00189 to state lncRNA.
2. 2. application according to claim 1, which is characterized in that the sequence of the LINC00189 such as SEQ ID NO.1 institutes Show.
3. 3. application according to claim 1, which is characterized in that the lncRNA further includes LOC105376014.
4. 4. application according to claim 3, which is characterized in that the product includes：Hybridize skill by sequencing technologies, nucleic acid Art, nucleic acid amplification technologies or the method for immunoassays test right require the expression of any one of the 1-3 lncRNA.
5. 5. a kind of application of product in the tool for preparing diagnosing ischemia cerebral apoplexy, the product includes chip, preparation or examination Agent box, which is characterized in that the product can measure the expression water of lncRNA as described in any one of claims 1-3 in sample It is flat.
6. 6. application according to claim 5, which is characterized in that the chip includes：Solid phase carrier；And it is orderly fixed on Oligonucleotide probe on the solid phase carrier, the oligonucleotide probe specifically correspond to any one of claim 1-3 Some or all of described lncRNA sequences.
7. 7. application according to claim 5, which is characterized in that the kit includes to any one of claim 1-3 institutes The lncRNA stated has probe, genetic chip or the PCR primer of detection specificity.
8. 8. application according to claim 7, which is characterized in that the PCR primer sequence of detection LINC00189 specificity is such as Shown in SEQ ID NO.3 and SEQ ID NO.4；Detect the PCR primer sequence such as SEQ ID NO.5 of LOC105376014 specificity Shown in SEQ ID NO.6.